Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display session

21P - Transcriptomic mapping of integrins and inmune activation in High- Grade Serous Ovarian Cancer.

Date

07 Mar 2022

Session

e-Poster Display session

Presenters

Katerin Rojas Laimito

Citation

Annals of Oncology (2022) 33 (suppl_1): S9-S12. 10.1016/annonc/annonc839

Authors

K.I. Rojas Laimito1, A. Ocana Fernandez2, M..V. Villena3, J.L. Gonzalez L.2, J. Puente V.2, M.J. Rubio4, H. García-Martínez5, J. Garcia-Donas6, L. Manso S.3

Author affiliations

  • 1 University Hospital 12 De Octubre, Madrid/ES
  • 2 Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC) and CIBERONC, Madrid/ES
  • 3 Hospital Universitario 12 de Octubre, Madrid/ES
  • 4 University Hospital Reina Sofia, Cordoba/ES
  • 5 Hospital Morales Meseguer, Murcia/ES
  • 6 Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid/ES
More

Abstract 21P

Background

Integrins, transmembrane receptors that mediade cell-extracellular matrix and cell-cell interaction, have been linked to cancer features. A less explores function of integrins in cancer is their role in leukocyte homing and activation. Understanding their role and relationship with immune infiltrates and immune checkpoints is an area of interest in cancer research.

Methods

The gene expression of 10 different integrins was explored in relation with ovarian cancer patient outcome using transcriptomic data (Affymetrix dataset, exploratory cohort) and the METABRIC study (validation cohort). The TIMER online tool was used to explore the association of the identified integrins and immune infiltration, and the TCGA and METABRIC studies to analyze the correlation between integrin expression and genomic signatures of immune activation.

Results

We identified 2 individual genes which encode for integrin a and b subunits, ITGAE and ITGA2, which predict favorable prognosis in High- Grade Serous Ovarian Cancer. Their expression positively correlated with the presence of immune infiltrates within the tumor (CD8+ cells and dendritic cells) with markers of T cell activation and antigen presentation, and with gene signatures of immune surveillance (cytotoxic T lymphocyte activation and IFN gamma signature). By contrast those integrins which predicted for detrimental outcome (ITGAM, ITGA4, ITGB2, ITGAV, ITGAL and ITGAX). Their expression positively correlated with the presence of immune infiltrates within the tumor (dendritic cells, neutrophils, macrophages, CD8+ T cells and B cells).

Conclusions

Our analysis identifies two integrin signatures composed of 2 genes with favorable prognosis and 6 genes with poor prognosis; with potential to recognize immune infiltrated and activated high-grade serous ovarian cancer.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.